Mainz Biomed Announces Year End 2021 Results
BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ)…
News
Sirona Biochem Subsidiary, TFChem, Awarded Financing in Partnership with French Government
VANCOUVER, British Colombia, March 09, 2022 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE:…
iOnctura to Present Preclinical Data on its Clinical Stage Autotaxin Inhibitor, IOA-289, at AACR
GENEVA, March 09, 2022 (GLOBE NEWSWIRE) — iOnctura SA, a clinical-stage oncology company targeting core…
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
At American Association for Cancer Research Annual Meeting 2022New Orleans, April 8 – 13 NANTES,…
Orion’s collaboration partner Bayer submits applications in the U.S. and EU for additional indication of darolutamide
ORION CORPORATION PRESS RELEASE 9 March 2022 at 8.30 EET Orion’s collaboration partner Bayer submits…
Dance grows its electric mobility subscription to Hamburg, Munich, Vienna and Paris while expanding its product line to include electric mopeds
Dance grows its electric mobility subscription internationally The Dance One Step, Dance Moped and Dance…
Xigem Technologies Offers Solutions for Ongoing Shift to a Remote Economy
Post-Pandemic Business Success will be Driven by Ability to Adapt to Remote Model Toronto, Ontario–(Newsfile…
Sequana Medical to Present at BioCapital Europe and Oppenheimer’s Annual Healthcare Conference
GHENT, Belgium, March 09, 2022 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA, the…
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating…
Efinix® Hires Greg Barrett as CFO Completing Executive Team to Fuel Next Phase of Company Growth
Barrett brings more than three decades of industry experience at Supermicro, Rambus, Micron and Altera…
C3.AI SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against C3.ai, Inc. – AI
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of…
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced…
SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action Against C3.ai, Inc.
SAN DIEGO–(BUSINESS WIRE)–$AI #IPO—The Class: Shareholder rights law firm Robbins LLP reminds investors that a…
Metropolitan Increases Call for Conservation With $10.5 Million Investment in Public Outreach
Campaign asks public to increase water saving as state enters third year of drought LOS…
C3.AI ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against C3.ai, Inc. and Encourages Investors to Contact the Firm
NEW YORK–(BUSINESS WIRE)–#C3–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces…
SchoolMint to Partner with LPTFA to Renovate Historic Warehouse in Downtown Lafayette into State-of-the-Art Global Headquarters
LAFAYETTE, La.–(BUSINESS WIRE)–SchoolMint®, the leading provider of Strategic Enrollment Management and positive behavior products for…
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022
Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in high-grade B-cell…
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m….
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting
Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor…
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral…